undamentalytics Newsletter
Sign in

Abcellera Biologics Inc. income statement

In fiscal 2025, Abcellera Biologics Inc. reported revenue of $75.1m, up 160.6% on the year before, operating income of −$217m (a -289.0% margin) and net income of −$146m, or −$0.49 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue1223337548538297566
Research and development102962108176167187198
Selling and marketing147111413——
General and administrative3124255758583—
Operating income−4156204217−237−315−217−225
Income before tax−2158219239−174−200−178−197
Income tax—396681−28−38−31−32
Net income−2119153159−146−163−146−165
Diluted EPS−$0.01$0.45$0.48$0.50−$0.51−$0.55−$0.49−$0.55
Diluted shares (average)151m263m318m315m289m294m299m302m
EBITDA−3161219244−213−302−199−204

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ABCL vs CYTKABCL vs CUVLABCL vs RXRX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Abcellera Biologics Inc.'s SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Abcellera Biologics Inc.